Expression analysis of SOX2 and SOX9 in patients with oral squamous cell carcinoma.
OSCC
SOX2
SOX9
oral cancer
survival
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
23 Aug 2024
23 Aug 2024
Historique:
revised:
12
08
2024
received:
03
06
2024
accepted:
15
08
2024
medline:
24
8
2024
pubmed:
24
8
2024
entrez:
24
8
2024
Statut:
aheadofprint
Résumé
Lately SOX2 and SOX9, transcription factors associated with stemness-like phenotypes of cancer cells, have been linked to tumor growth, metastasis, and resistance to therapy. This study aimed on evaluating the expression of SOX2 and SOX9 in a large cohort of patients with OSCC including primary and recurrent tumors and corresponding lymph node metastases. Semiautomatic digital pathology scoring was used to determine protein expression and survival analysis was performed to evaluate its prognostic significance. We found a significant downregulation of SOX9 from primary disease to lymph node metastases (p < 0.001). SOX9 expression and the subgroup SOX2 These results indicate the relevant role of SOX2 and SOX9 in patients with OSCC and show the clinical relevance for further investigation on the molecular mechanisms underlying SOX-related gene expression.
Sections du résumé
BACKGROUND
BACKGROUND
Lately SOX2 and SOX9, transcription factors associated with stemness-like phenotypes of cancer cells, have been linked to tumor growth, metastasis, and resistance to therapy.
METHODS
METHODS
This study aimed on evaluating the expression of SOX2 and SOX9 in a large cohort of patients with OSCC including primary and recurrent tumors and corresponding lymph node metastases. Semiautomatic digital pathology scoring was used to determine protein expression and survival analysis was performed to evaluate its prognostic significance.
RESULTS
RESULTS
We found a significant downregulation of SOX9 from primary disease to lymph node metastases (p < 0.001). SOX9 expression and the subgroup SOX2
CONCLUSIONS
CONCLUSIONS
These results indicate the relevant role of SOX2 and SOX9 in patients with OSCC and show the clinical relevance for further investigation on the molecular mechanisms underlying SOX-related gene expression.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Head & Neck published by Wiley Periodicals LLC.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394‐424.
Shield KD, Ferlay J, Jemal A, et al. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin. 2017;67(1):51‐64.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7‐34.
de Vicente JC, Donate‐Pérez Del Molino P, Rodrigo JP, et al. SOX2 expression is an independent predictor of oral cancer progression. J Clin Med. 2019;8(10):1744.
Fu TY, Hsieh IC, Cheng JT, et al. Association of OCT4, SOX2, and NANOG expression with oral squamous cell carcinoma progression. J Oral Pathol Med. 2016;45(2):89‐95.
Chhetri DK, Rawnsley JD, Calcaterra TC. Carcinoma of the buccal mucosa. Otolaryngol Head Neck Surg. 2000;123(5):566‐571.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359‐E386.
Global, regional, and national age‐sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151‐1210.
Wu HT, Chen WT, Li GW, et al. Analysis of the differentially expressed genes induced by cisplatin resistance in oral squamous cell carcinomas and their interaction. Front Genet. 2019;10:1328.
Voronkova MA, Rojanasakul LW, Kiratipaiboon C, Rojanasakul Y. The SOX9‐aldehyde dehydrogenase Axis determines resistance to chemotherapy in non‐small‐cell lung cancer. Mol Cell Biol. 2020;40(2):e00307‐e00319.
Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755‐768.
Kuşoğlu A, Biray AÇ. Cancer stem cells: a brief review of the current status. Gene. 2019;681:80‐85.
Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer. 2013;13(10):727‐738.
Yang L, Shi P, Zhao G, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8.
Chaudhary A, Raza SS, Haque R. Transcriptional factors targeting in cancer stem cells for tumor modulation. Semin Cancer Biol. 2023;88:123‐137.
Boumahdi S, Driessens G, Lapouge G, et al. SOX2 controls tumour initiation and cancer stem‐cell functions in squamous‐cell carcinoma. Nature. 2014;511(7508):246‐250.
Lengerke C, Fehm T, Kurth R, et al. Expression of the embryonic stem cell marker SOX2 in early‐stage breast carcinoma. BMC Cancer. 2011;11:42.
Koyama‐Nasu R, Haruta R, Nasu‐Nishimura Y, et al. The pleiotrophin‐ALK axis is required for tumorigenicity of glioblastoma stem cells. Oncogene. 2014;33(17):2236‐2244.
Wilbertz T, Wagner P, Petersen K, et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol. 2011;24(7):944‐953.
Carrasco‐Garcia E, Santos JC, Garcia I, et al. Paradoxical role of SOX2 in gastric cancer. Am J Cancer Res. 2016;6(4):701‐713.
Zhang XH, Wang W, Wang YQ, Zhu L, Ma L. The association of SOX2 with clinical features and prognosis in colorectal cancer: a meta‐analysis. Pathol Res Pract. 2020;216(1):152769.
Chung JH, Jung HR, Jung AR, et al. SOX2 activation predicts prognosis in patients with head and neck squamous cell carcinoma. Sci Rep. 2018;8(1):1677.
Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell‐cycle arrest and apoptosis. Br J Cancer. 2008;98(4):824‐831.
Jo A, Denduluri S, Zhang B, et al. The versatile functions of Sox9 in development, stem cells, and human diseases. Genes Dis. 2014;1(2):149‐161.
Scott CE, Wynn SL, Sesay A, et al. SOX9 induces and maintains neural stem cells. Nat Neurosci. 2010;13(10):1181‐1189.
Matheu A, Collado M, Wise C, et al. Oncogenicity of the developmental transcription factor Sox9. Cancer Res. 2012;72(5):1301‐1315.
Hong Y, Chen W, Du X, et al. Upregulation of sex‐determining region Y‐box 9 (SOX9) promotes cell proliferation and tumorigenicity in esophageal squamous cell carcinoma. Oncotarget. 2015;6(31):31241‐31254.
Chakravarty G, Moroz K, Makridakis NM, et al. Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer. Exp Biol Med (Maywood). 2011;236(2):145‐155.
Lü B, Fang Y, Xu J, et al. Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol. 2008;130(6):897‐904.
Wang HY, Lian P, Zheng PS. SOX9, a potential tumor suppressor in cervical cancer, transactivates p21WAF1/CIP1 and suppresses cervical tumor growth. Oncotarget. 2015;6(24):20711‐20722.
Barbosa S, Laureano NK, Hadiwikarta WW, et al. The role of SOX2 and SOX9 in radioresistance and tumor recurrence. Cancers (Basel). 2024;16(2):439.
Züllig L, Roessle M, Weber C, et al. High sex determining region Y‐box 2 expression is a negative predictor of occult lymph node metastasis in early squamous cell carcinomas of the oral cavity. Eur J Cancer. 2013;49(8):1915‐1922.
Du L, Yang Y, Xiao X, et al. Sox2 nuclear expression is closely associated with poor prognosis in patients with histologically node‐negative oral tongue squamous cell carcinoma. Oral Oncol. 2011;47(8):709‐713.
Michifuri Y, Hirohashi Y, Torigoe T, et al. High expression of ALDH1 and SOX2 diffuse staining pattern of oral squamous cell carcinomas correlates to lymph node metastasis. Pathol Int. 2012;62(10):684‐689.
Freier K, Joos S, Flechtenmacher C, et al. Tissue microarray analysis reveals site‐specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res. 2003;63(6):1179‐1182.
Bankhead P, Loughrey MB, Fernandez JA, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.
Sumita Y, Yamazaki M, Maruyama S, et al. Cytoplasmic expression of SOX9 as a poor prognostic factor for oral squamous cell carcinoma. Oncol Rep. 2018;40(5):2487‐2496.
Lin SC, Chou YT, Jiang SS, et al. Epigenetic switch between SOX2 and SOX9 regulates cancer cell plasticity. Cancer Res. 2016;76(23):7036‐7048.
Qiao B, He B, Cai J, Yang W. The expression profile of Oct4 and Sox2 in the carcinogenesis of oral mucosa. Int J Clin Exp Pathol. 2014;7(1):28‐37.
Schröck A, Göke F, Wagner P, et al. Sex determining region Y‐box 2 (SOX2) amplification is an independent indicator of disease recurrence in sinonasal cancer. PLoS One. 2013;8(3):e59201.
Bayo P, Jou A, Stenzinger A, et al. Loss of SOX2 expression induces cell motility via vimentin up‐regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma. Mol Oncol. 2015;9(8):1704‐1719.
Jana S, Madhu Krishna B, Singhal J, et al. SOX9: the master regulator of cell fate in breast cancer. Biochem Pharmacol. 2020;174:113789.
Zhou CH, Ye LP, Ye SX, et al. Clinical significance of SOX9 in human non‐small cell lung cancer progression and overall patient survival. J Exp Clin Cancer Res. 2012;31(1):18.
Khorani K, Schwaerzler J, Burkart S, et al. Establishment of a plasticity‐associated risk model based on a SOX2‐ and SOX9‐related gene set in head and neck squamous cell carcinoma. Mol Cancer Res. 2021;19(10):1676‐1687.
Sharma A, Cao EY, Kumar V, et al. Longitudinal single‐cell RNA sequencing of patient‐derived primary cells reveals drug‐induced infidelity in stem cell hierarchy. Nat Commun. 2018;9(1):4931.
Domenici G, Aurrekoetxea‐Rodríguez I, Simões BM, et al. A Sox2‐Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells. Oncogene. 2019;38(17):3151‐3169.